Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer

The goal of this retrospective observational study is to assess the clinical utility of plasma-based EGFR testing for detection and longitudinal monitoring of the acquired T790M resistance mutation in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first- or second-generation EGFR tyrosine kinase inhibitors in routine clinical practice in Tunisia. The main questions it aims to answer are: * What is the detection rate of EGFR T790M mutation in plasma at the time of disease progression? * Does repeated liquid biopsy increase the cumulative detection of T790M? * Is T790M emergence associated with baseline clinical and molecular characteristics? * Is T790M status associated with progression-free survival? Participants underwent plasma sampling for circulating tumor DNA analysis during follow-up, and clinical and molecular data were retrospectively collected from medical records to evaluate mutation dynamics and outcomes.

NCT Number	NCT07475637
Lead Sponsor	Faculty of Medicine of Tunis Collaborators: Hopital Charles Nicolle
Conditions	Non-Small Cell Lung Cancer
Enrollment	70 participants
Start Date	2023-03-01
Primary Completion	2025-12-30 (estimated)
Study Completion	2025-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-19